Abcellera Biologics Inc. (ABCL) Stock Price & Analysis
Abcellera Biologics Inc. (ABCL) fell 6.35% to USD 5.31 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
ABCL last closed at USD 5.67; the session ranged USD 5.29–5.74 on volume of 6,255,859 shares. Market capitalization is $1.62B, with a 52-week range of USD 2.75–8.44 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 5.31 |
|---|---|
| Change | ▼ 6.35% (down) |
| Previous Close | USD 5.67 |
| Open | USD 5.68 |
| Day Range | USD 5.29 – 5.74 |
| 52-Week Range | USD 2.75 – 8.44 |
| Volume | 6,255,859 shares |
| Market Cap | $1.62B |
| Exchange | NMS |
Technical Analysis (ABCL)
Nexqual's technical model rates ABCL "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.18 (neutral) |
| vs SMA50 | Below (USD 5.96) |
| MACD | -0.13 (negative) |
Analyst Ratings (ABCL)
Wall Street analysts rate ABCL "Strong Buy" based on 8 analysts, with a mean price target of USD 10.5 (range USD 7–13), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 10.5 |
| High Target | USD 13 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (ABCL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $7.78M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.14 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.03 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.16 ▼ miss |
| 2025-06-30 | USD -0.12 vs est -0.16 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (ABCL)
| Total Revenue | $79.21M |
|---|---|
| Revenue Growth (YoY) | +96.30% |
| Gross Margin | -141.13% |
| Operating Margin | -691.75% |
| Profit Margin | -181.74% |
| ROE | -14.68% |
| Debt / Equity | 14.94 |
| Current Ratio | 14.05 |
| Total Cash | $504.73M |
| Total Debt | $140.18M |
| Free Cash Flow | $-114.04M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (ABCL)
Nexqual rates Abcellera Biologics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +161% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $505M cash vs $140M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$114M, burning cash |
| Efficiency | Critical — ROE -15%, ROA -10.0% |
Ownership (ABCL)
| Insider Ownership | +23.04% |
|---|---|
| Institutional Ownership | +43.43% |
| Shares Outstanding | 305.38M |
| Float | 205.09M |
| Short % of Float | +20.61% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (ABCL)
Abcellera Biologics Inc. is led by Carl L.G. Hansen (age 50), CEO, President & Chairperson, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO, President & Chairperson | Carl L.G. Hansen (age 50) |
|---|---|
| Chief Financial Officer | Andrew Booth (age 51) |
| CTO & Director | Veronique Lecault (age 40) |
Major Backers & Investors (ABCL)
Notable institutional backers of Abcellera Biologics Inc. include Baker Bros. Advisors, LP, Capital Group, SmallCap World Fund Inc, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 9.91% |
| Capital Group | 4.38% |
| SmallCap World Fund Inc | 4.38% |
| Two Sigma Investments, LP | 3.46% |
| TD Waterhouse Canada Inc. | 3.13% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.48% |
| UBS Group AG | 1.38% |
| ArrowMark Colorado Holdings LLC | 1.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.13% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Abcellera Biologics Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Platform We have invested approximately $1 billion over nearly 15 years to build a differentiated and vertically-integrated antibody drug platform.
- We anticipate initiating Phase 1/2 clinical trials for ABCL688 and ABCL386 in 2027. • Opened our clinical manufacturing facility , which completes a multi-year investment to build our integrated platform for creating antibody medicines.
- Our integrated platform for antibody drug discovery and development We discover antibodies from natural immune responses, which are pre-enriched for antibodies with higher target-binding specificity and developability than those generated by synthetic methods.
- Our competitive advantage consists not of a single proprietary technology, but of the integration of proprietary know-how, specialized multidisciplinary teams, and the physical infrastructure necessary to advance programs from target to the clinic.
Partnerships
- We discovered ABCL575 during our collaboration with EQRx Inc. ("EQRx") as part of a co-development program that began in 2021.
- In late 2023, with our platform near complete, we committed to transitioning from a partnership model to a clinical-stage biotechnology company developing our own pipeline of drug candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | USD 25.1 | ▼ 5.78% |
| CERT | Certara, Inc. | USD 7.51 | ▲ 9% |
| NTLA | Intellia Therapeutics, Inc. | USD 10.73 | ▼ 3.59% |
| RXRX | Recursion Pharmaceuticals, Inc. | USD 2.96 | ▼ 0.67% |
| SDGR | Schrodinger, Inc. | USD 14.97 | ▼ 0.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.